NCT05108519: Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Patients must be receiving any anti-VEGF-related regimen (e.g. Avastin/bevacizumab)

Comments are closed.

Up ↑